178 related articles for article (PubMed ID: 37106163)
41. Demethylating therapy increases cytotoxicity of CD44v6 CAR-T cells against acute myeloid leukemia.
Tang L; Kong Y; Wang H; Zou P; Sun T; Liu Y; Zhang J; Jin N; Mao H; Zhu X; Wang J; Meng F; You Y
Front Immunol; 2023; 14():1145441. PubMed ID: 37180104
[TBL] [Abstract][Full Text] [Related]
42. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
[TBL] [Abstract][Full Text] [Related]
43. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia.
Fan S; Wang T; You F; Zhang T; Li Y; Ji C; Han Z; Sheng B; Zhai X; An G; Meng H; Yang L
Eur J Med Res; 2023 Mar; 28(1):129. PubMed ID: 36941687
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic FLT3 CAR T Cells with an Off-Switch Exhibit Potent Activity against AML and Can Be Depleted to Expedite Bone Marrow Recovery.
Sommer C; Cheng HY; Nguyen D; Dettling D; Yeung YA; Sutton J; Hamze M; Valton J; Smith J; Djuretic I; Chaparro-Riggers J; Sasu BJ
Mol Ther; 2020 Oct; 28(10):2237-2251. PubMed ID: 32592688
[TBL] [Abstract][Full Text] [Related]
45. Chimeric antigen receptor T cell therapies for acute myeloid leukemia.
Gu B; Chu J; Wu D
Front Med; 2020 Dec; 14(6):701-710. PubMed ID: 33263835
[TBL] [Abstract][Full Text] [Related]
46. Generation of Suicide Gene-Modified Chimeric Antigen Receptor-Redirected T-Cells for Cancer Immunotherapy.
Minagawa K; Al-Obaidi M; Di Stasi A
Methods Mol Biol; 2019; 1895():57-73. PubMed ID: 30539529
[TBL] [Abstract][Full Text] [Related]
47. Chimeric antigen receptor T-cell therapy for T-ALL and AML.
Wei W; Yang D; Chen X; Liang D; Zou L; Zhao X
Front Oncol; 2022; 12():967754. PubMed ID: 36523990
[TBL] [Abstract][Full Text] [Related]
48. CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia.
Gomes-Silva D; Atilla E; Atilla PA; Mo F; Tashiro H; Srinivasan M; Lulla P; Rouce RH; Cabral JMS; Ramos CA; Brenner MK; Mamonkin M
Mol Ther; 2019 Jan; 27(1):272-280. PubMed ID: 30391141
[TBL] [Abstract][Full Text] [Related]
49. Anti-Acute Myeloid Leukemia Activity of CD38-CAR-T Cells with PI3Kδ Downregulation.
An N; Pan Y; Yang L; Zhang Q; Deng S; Zhang Q; Du X
Mol Pharm; 2023 May; 20(5):2426-2435. PubMed ID: 37021820
[TBL] [Abstract][Full Text] [Related]
50. Chimeric Antigen Receptor T-cell Therapy for Acute Myeloid Leukemia.
Bi X; Hsu J; Gergis M; Yang Y; Yi D; Gergis U
Hematol Oncol Stem Cell Ther; 2022 Dec; 15(3):131-136. PubMed ID: 36537909
[TBL] [Abstract][Full Text] [Related]
51. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
52. Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia.
Fan M; Li M; Gao L; Geng S; Wang J; Wang Y; Yan Z; Yu L
J Hematol Oncol; 2017 Aug; 10(1):151. PubMed ID: 28851445
[TBL] [Abstract][Full Text] [Related]
53. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia.
Le Q; Castro S; Tang T; Loeb AM; Hylkema T; McKay CN; Perkins L; Srivastava S; Call L; Smith J; Leonti A; Ries R; Pardo L; Loken MR; Correnti C; Fiorenza S; Turtle CJ; Riddell S; Tarlock K; Meshinchi S
Clin Cancer Res; 2021 Oct; 27(20):5718-5730. PubMed ID: 34380639
[TBL] [Abstract][Full Text] [Related]
55. Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells.
Lynn RC; Poussin M; Kalota A; Feng Y; Low PS; Dimitrov DS; Powell DJ
Blood; 2015 May; 125(22):3466-76. PubMed ID: 25887778
[TBL] [Abstract][Full Text] [Related]
56. Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells.
Wang Y; Xu Y; Li S; Liu J; Xing Y; Xing H; Tian Z; Tang K; Rao Q; Wang M; Wang J
J Hematol Oncol; 2018 May; 11(1):60. PubMed ID: 29716633
[TBL] [Abstract][Full Text] [Related]
57. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo.
Pizzitola I; Anjos-Afonso F; Rouault-Pierre K; Lassailly F; Tettamanti S; Spinelli O; Biondi A; Biagi E; Bonnet D
Leukemia; 2014 Aug; 28(8):1596-605. PubMed ID: 24504024
[TBL] [Abstract][Full Text] [Related]
58. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
59. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
60. Novel immunotherapies in the treatment of AML: is there hope?
Subklewe M; Bücklein V; Sallman D; Daver N
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):691-701. PubMed ID: 38066884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
